Ilke Nalbantoglu, MD
Associate Professor of PathologyCards
About
Titles
Associate Professor of Pathology
Appointments
Pathology
Associate Professor on TermPrimary
Other Departments & Organizations
- Gastrointestinal (GI) & Liver Pathology
- Pathology
- Surgical Pathology
- Yale Medicine
Education & Training
- MD
- Ege University School of Medicine, M.D.
Research
Publications
2025
Margin clearance and post‐procedure ablation decrease recurrence risk in endoscopic mucosal resections for Barrett's‐related neoplasia
Bell P, Kaul V, Bittner K, Chen I, Huber A, Sagan O, Chen W, Nalbantoglu I, Gonzalez R. Margin clearance and post‐procedure ablation decrease recurrence risk in endoscopic mucosal resections for Barrett's‐related neoplasia. Histopathology 2025 PMID: 40964766, DOI: 10.1111/his.15554.Peer-Reviewed Original ResearchEndoscopic mucosal resectionHighest-grade lesionsLocal disease recurrenceHigh-grade dysplasiaDisease recurrenceRecurrence riskMargin statusTumor buddingMucosal resectionRisk of local disease recurrenceBarrett's-related neoplasiaLow-stage carcinomasLow-grade dysplasiaCancer invasion depthRelationship to recurrenceGlandular neoplasiaBarrett’s-related adenocarcinomaHistopathological factorsLymphovascular invasionMargin clearanceTumor depthPatient ageRetrospective studyLesion depthOesophageal dysplasiaPatterns of sialyl-Lewis X expression predict gastric histopathology
Vargas N, Quiroga A, Chaves J, Bolaños H, Nalbantoglu I, Astaiza C, Wu Y, Sáenz J. Patterns of sialyl-Lewis X expression predict gastric histopathology. Diagnostic Pathology 2025, 20: 76. PMID: 40551130, PMCID: PMC12183862, DOI: 10.1186/s13000-025-01673-8.Peer-Reviewed Original ResearchConceptsChronic atrophic gastritisChronic non-atrophic gastritisGastric pathologyAssociated with chronic atrophic gastritisIntestinal metaplasiaProgression to gastric cancerSLex expressionPre-cancerous lesionsNon-atrophic gastritisGastric pre-cancerous lesionsHistological diagnosisPre-cancerous changesGlandular distributionAntrum biopsiesAdult patientsGastric corpusAtrophic gastritisChronic inflammationGastric cancerHistological markersHistological assessmentGastric histopathologyGastric epitheliumIntroductionGastric cancerBiopsyApobec1 complementation factor overexpression promotes hepatic steatosis, fibrosis, and hepatocellular cancer
Blanc V, Riordan J, Soleymanjahi S, Nadeau J, Nalbantoglu I, Xie Y, Molitor E, Madison B, Brunt E, Mills J, Rubin D, Ng I, Ha Y, Roberts L, Davidson N. Apobec1 complementation factor overexpression promotes hepatic steatosis, fibrosis, and hepatocellular cancer. Journal Of Clinical Investigation 2025, 135: e194717. PMID: 40454486, PMCID: PMC12126243, DOI: 10.1172/jci194717.Peer-Reviewed Original ResearchIdentification of differential epigenetic landscapes in subtypes of appendiceal cancer.
Ladel L, Tan W, Sailo B, Das P, Tyagi A, Nalbantoglu I, Sharma A, Ahuja N. Identification of differential epigenetic landscapes in subtypes of appendiceal cancer. Journal Of Clinical Oncology 2025, 43: 4199-4199. DOI: 10.1200/jco.2025.43.16_suppl.4199.Peer-Reviewed Original ResearchDifferentially Methylated RegionsAppendiceal cancerAdvanced neoplasiaColorectal cancerCpG islandsAppendiceal neoplasmsNormal tissuesMalignant subtypeGenomic dataLow-grade appendiceal mucinous neoplasmEpigenetic landscapeHeterogeneous group of malignanciesPromoter regionAnalysis of CpG islandsAppendiceal mucinous neoplasmGroup of malignanciesNon-neoplastic controlsEnzymatic methyl-seqHypermethylated CpG islandsSingle-base resolutionHypomethylated CpG islandsRare malignancyQ-value cutoffMucinous neoplasmsEpigenetic clustering
2024
Validation of Metallothionein Immunohistochemistry as a Highly Sensitive Screening Test for Wilson Disease
Stokes N, Patil A, Adeyi O, Bhalla A, Brown I, Byrnes K, Calderaro J, Chen D, Chen W, Cooper C, Dhall D, Frankel W, Gooch G, Gonzalez R, Hammer S, Hale G, Lagana S, McKenzie C, Allende D, Moreira R, Nakhleh R, Nalbantoglu I, Pai R, Salomao M, Schaeffer D, Shih A, Shin J, Simoes C, Vij M, Rela M, Xue Y, Yantiss R, Sabatto B, Graham R. Validation of Metallothionein Immunohistochemistry as a Highly Sensitive Screening Test for Wilson Disease. Modern Pathology 2024, 38: 100628. PMID: 39384020, DOI: 10.1016/j.modpat.2024.100628.Peer-Reviewed Original ResearchWilson's diseaseHistological featuresRare autosomal recessive conditionChronic cholestatic diseaseProtean clinical manifestationsEvaluation of patientsAutosomal recessive conditionSensitive screening testCase of WDCost-effective screening toolRoutine histologic sectionsMedian ageNeedle biopsyCholestatic diseasesWD patientsFibrosis stageClinical manifestationsHistopathological patternsATP7B mutationsHistological patternWD diagnosisTissue specimensAssessed patientsImmunohistochemistryMasson's trichromeValidation of a whole slide image management system for metabolic‐associated steatohepatitis for clinical trials
Pulaski H, Mehta S, Manigat L, Kaufman S, Hou H, Nalbantoglu I, Zhang X, Curl E, Taliano R, Kim T, Torbenson M, Glickman J, Resnick M, Patel N, Taylor C, Bedossa P, Montalto M, Beck A, Wack K. Validation of a whole slide image management system for metabolic‐associated steatohepatitis for clinical trials. The Journal Of Pathology Clinical Research 2024, 10: e12395. PMID: 39294925, PMCID: PMC11410674, DOI: 10.1002/2056-4538.12395.Peer-Reviewed Original ResearchConceptsClinical trialsAssessment of disease activityOverall percent agreementLiver biopsyDisease activityPathological assessmentWashout periodHistological assessmentEndpoint assessmentGold standardPercent agreementScoring systemExpert pathologistsSteatohepatitisAverage agreementDigital scoresPathologistsTrials
2023
Clinical and Pathological Correlation in Concomitant Celiac Disease and Eosinophilic Esophagitis Suggests Separate Etiologies
Castrodad-Rodríguez C, Cheng J, Westerhoff M, Liang G, Lin J, Nalbantoglu I, Hu S, Sekhri R, Panarelli N. Clinical and Pathological Correlation in Concomitant Celiac Disease and Eosinophilic Esophagitis Suggests Separate Etiologies. International Journal Of Surgical Pathology 2023, 32: 27-34. PMID: 37050846, DOI: 10.1177/10668969231167526.Peer-Reviewed Original ResearchConcomitant celiac diseaseEosinophilic esophagitisStudy patientsCeliac diseasePeak esophageal eosinophil countsCeliac disease symptomsMost study patientsGluten-free dietPatients meeting criteriaDisease-related symptomsEsophageal eosinophil countsDuodenal histologyAtopic conditionsEsophageal symptomsHistological severitySubepithelial fibrosisEosinophil countMarsh IIPathological featuresPathological correlationEsophagitisSeparate etiologiesPatientsMeeting criteriaControl groupApproach to the liver biopsy diagnosis of adult cholangiopathies
Nalbantoglu I, Misdraji J. Approach to the liver biopsy diagnosis of adult cholangiopathies. Diagnostic Histopathology 2023, 29: 23-35. DOI: 10.1016/j.mpdhp.2022.10.004.Commentaries, Editorials and LettersPrimary biliary cholangitisChronic biliary disordersBiliary cholangitisBiliary disordersPrimary sclerosing cholangitisLiver biopsy diagnosisAutoimmune hepatitisSclerosing cholangitisAdult patientsInflammatory variantClinical featuresHistologic featuresHistologic findingsBiopsy diagnosisDifferential diagnosisCholangitisCorrect diagnosisCholangiopathyClinical informationCareful assessmentDiagnosisDisordersWide spectrumVast majorityHepatitis
2022
Liver allograft findings of donation after cardiac death versus brain death in recipients with hepatitis C related cirrhosis: a matched histologic comparison
Byrnes K, Vachharajani N, Doyle MM, Nalbantoglu I. Liver allograft findings of donation after cardiac death versus brain death in recipients with hepatitis C related cirrhosis: a matched histologic comparison. Human Pathology 2022, 122: 25-31. PMID: 35085598, DOI: 10.1016/j.humpath.2022.01.005.Peer-Reviewed Original ResearchConceptsBiliary complicationsDCD casesLiver allograftsCardiac deathHistologic featuresBrain death (DBD) recipientsDCD liver allograftsPostoperative biliary complicationsBile duct injuryCold ischemia timeHepatitis C virusOrgan transplantation increasesBiliary alterationsDBD recipientsDCD allograftsDCD recipientsPortal edemaDuct injuryGraft survivalHepatitis CPortal inflammationOverall survivalTransplantation increasesLiver biopsyClinical outcomes
2021
Yale Cancer Center Precision Medicine Tumor Board: molecular findings alter a diagnosis and treatment plan
Gibson JA, Finberg KE, Nalbantoglu I, Cecchini M, Ganzak A, Walther Z, Sklar JL, Eder JP, Goldberg SB. Yale Cancer Center Precision Medicine Tumor Board: molecular findings alter a diagnosis and treatment plan. The Lancet Oncology 2021, 22: 306-307. PMID: 33662283, DOI: 10.1016/s1470-2045(20)30683-5.Peer-Reviewed Original Research
Clinical Trials
Current Trials
Wilson Disease Registry
HIC ID1609018429REGRoleSub InvestigatorPrimary Completion Date10/01/2022Recruiting ParticipantsGenderBoth